News Briefs: Share of Highly Rated MA-PD Plans Will Drop in 2023

On Oct. 7, CMS released the 2023 Medicare Advantage Star Ratings, revealing that 51.3% of Medicare Advantage Prescription Drug (MA-PD) plan contracts will be rated 4 stars and above next year. That’s down from 68.4% of 2022 MA-PD contracts, Citi analyst Jason Cassorla observed in a note to investors. On an enrollment basis, 72.1% of current MA-PD enrollees are in plans rated 4 stars and above for 2023, down from 89.7% in 2022. “The lower MA Star Ratings for 2023 on a [year-over-year] basis are largely a function of CMS removing many of the COVID-19-related guardrails and relaxed criteria that aided Stars performance for 2021-2022,” Cassorla pointed out. “Ratings for 2023 were also impacted by changes to how plans are rated with CMS a greater emphasis on the Consumer Assessment of Healthcare Providers and Systems survey.”

0 Comments
© 2024 MMIT
AIS Health Staff

AIS Health Staff

Related Posts

inside-congress
June 21

Reports Underscore Risk of Failing to Extend Enhanced ACA Subsidies

READ MORE
businessman-viewing-news-update-journalism-headline-on-a-laptop
June 21

News Briefs: Court Upholds ACA Preventive Services Coverage Mandate, for Now

READ MORE
finance-and-economy-chart
June 21

MCO Stock Performance, May 2024

READ MORE

GAIN THERAPEUTIC AREA-SPECIFIC INTEL TO DRIVE ACCESS FOR YOUR BRAND

Sign up for publications to get unmatched business intelligence delivered to your inbox.

subscribe today